Is Chronic Lymphocytic Leukemia an Autoimmune Disease?

Chronic lymphocytic leukemia is a blood cancer, not an autoimmune disease, but the boundary between the two is blurrier than in almost any other malignancy. CLL arises from a type of immune cell that, even in healthy people, patrols the line between recognizing foreign invaders and reacting to the body’s own tissues. Around one in ten people with CLL develops an autoimmune complication during the course of their illness, and the biology of the cancer itself is steeped in self-reactivity. Understanding why requires looking at how CLL cells originate, how they reshape the immune environment around them, and why treating the cancer can sometimes make autoimmune problems worse before they get better.

A Cancer That Breeds Autoimmune Complications

CLL is classified as a malignancy of B lymphocytes, the white blood cells responsible for producing antibodies. It is diagnosed and treated as a cancer, not as an immune disorder. Yet autoimmune complications show up alongside CLL far more often than alongside most other cancers. The most common are conditions where the immune system destroys the patient’s own blood cells: autoimmune hemolytic anemia (the body attacks its red blood cells), immune thrombocytopenia (it attacks platelets), pure red cell aplasia (it shuts down red blood cell production), and autoimmune granulocytopenia (it targets infection-fighting white cells).¹ These autoimmune blood disorders occur in roughly 10% of CLL patients overall.²

Autoimmune hemolytic anemia is by far the most frequent, affecting somewhere between 10% and 20% of CLL patients over the course of their disease, while immune thrombocytopenia occurs in a smaller fraction.³ These numbers are strikingly high compared to the general population, where autoimmune hemolytic anemia is rare. The fact that CLL preferentially triggers immune attacks on blood cells, rather than on joints, skin, or organs, turns out to be an important clue about what is actually going on biologically.

Why CLL Cells Are Primed for Self-Reactivity

Part of what makes CLL unusual among cancers is that its cells appear to descend from a particular pool of B cells that already sit at the intersection of immunity and self-recognition. In healthy people, some B cells carry surface receptors that weakly bind to the body’s own molecules. These “autoreactive” or “polyreactive” B cells are normally held in check. They serve useful housekeeping roles, like clearing debris from dying cells, and they overlap with the body’s first line of defense against infection. CLL is thought to arise from this subset of naturally self-reactive, CD5-positive B cells.⁴

Research into the surface receptors on CLL cells has strengthened this picture. Many CLL clones carry B-cell receptors that are strikingly similar from patient to patient, a phenomenon called stereotypy. These “stereotyped” receptors recognize a limited set of targets, including self-molecules like oxidized low-density lipoprotein (a form of modified cholesterol found on dying cells and arterial plaques) and even the B-cell receptor itself.⁵ One well-studied poor-prognosis subset of CLL specifically binds oxidized LDL, a molecule present on apoptotic cell debris and on some microbial surfaces.⁶

This means CLL is not a random mutation in any old B cell. The cancer disproportionately grows out of cells whose very identity involves recognizing the body’s own tissues. One proposal for how this unfolds is that B cells with self-reactive receptors undergo a series of normal safety edits in the bone marrow, like having their receptors modified and being pushed into a dormant state. When something goes wrong, these suppression mechanisms fail and the cells begin proliferating uncontrollably.⁷

Chronic Self-Stimulation and the Role of Antigens

B cells normally need to encounter their target antigen to stay active and multiply. In CLL, this signaling through the B-cell receptor appears crucial for the disease to take hold and progress. Some CLL cells can actually signal through their receptors without any outside antigen at all, a process called autonomous signaling. Studies have shown this self-stimulating capacity even in the precursor condition that sometimes precedes CLL, called monoclonal B-cell lymphocytosis.⁸

Researchers have also explored whether infections might kickstart CLL by stimulating B cells that happen to cross-react with the body’s own tissues. Using mouse models, one group found that while the B-cell receptors on CLL cells could recognize viral antigens, the leukemia cells preferentially selected light-chain components that let them also bind to a broad range of self-molecules. Neither acute nor chronic virus exposure directly accelerated the cancer. Instead, the emerging CLL clones were the ones whose receptors had evolved to cross-react with self-antigens.⁹ The implication is that infections may not directly cause CLL, but they could select for the B cells most prone to self-reactivity, which then become the seeds of malignancy.

Who Actually Makes the Damaging Autoantibodies

Here is where the story gets genuinely surprising. If CLL cells are inherently self-reactive, you might assume they are the ones producing the autoantibodies that destroy a patient’s red blood cells or platelets. But the evidence increasingly suggests otherwise. In most cases, the destructive autoantibodies seem to come from the patient’s remaining normal, polyclonal B cells, not from the malignant CLL clone itself.

A study of CLL patients who also developed myasthenia gravis (an autoimmune nerve-muscle disease) found that the antibodies causing the nerve damage were made by non-malignant B cells, not by the CLL cells. The researchers noted this parallels what has been described in CLL-associated autoimmune hemolytic anemia and immune thrombocytopenia as well: the CLL cells often carry autoreactive surface receptors, but the actual disease-causing antibodies appear to originate from normal “bystander” B cells that have been thrown off-kilter by the immune disruption CLL creates.¹⁰

The full picture is likely not so simple in every patient. The mechanism probably varies: in some cases the CLL cells may contribute to autoantibody production directly, in others they may present self-antigens in a way that activates neighboring T cells and bystander B cells, and in still others both processes may overlap.¹¹ One older review acknowledged that, at least for autoimmune hemolytic anemia, the exact cellular source of the autoantibody remains unresolved.¹² What is clear is that CLL fundamentally alters the immune landscape in a way that makes autoimmunity more likely, regardless of whether the cancer cells themselves are pulling the trigger.

How CLL Rewires the Immune System

CLL does not just add a population of malignant cells. It actively degrades the patient’s entire immune apparatus in ways that echo what goes wrong in classic autoimmune diseases. One of the central paradoxes of CLL is that patients are simultaneously immunodeficient and autoimmune-prone. Antibody levels in the blood drop steadily over time, a condition called hypogammaglobulinemia, leaving patients vulnerable to infections. At the same time, the immune system mounts misdirected attacks on the patient’s own blood cells.

A key explanation for this paradox involves how CLL cells take over the role of antigen-presenting cells. Because the expanding malignant B cells become the dominant immune cells in the body, they shape which signals T cells and other immune cells receive. When T-cell regulation deteriorates, the remaining normal B cells may become activated against self-antigens, particularly those found on blood cells.¹³

Regulatory T cells, which normally suppress inappropriate immune responses and prevent autoimmunity, are also disrupted in CLL. Their numbers are often elevated, yet their ability to maintain immune balance appears impaired. Dysfunction in this population is known to play a role in diseases ranging from type 1 diabetes to rheumatoid arthritis, and similar disruption in the CLL setting may explain why self-tolerance breaks down.¹⁴ Beyond cellular dysfunction, the local tissue environment in CLL is shaped by abnormal signaling molecules and cell-to-cell contacts that further warp immune function.¹⁵

Non-Blood Autoimmune Complications Are Rare But Real

Most of the autoimmune trouble in CLL targets blood cells, and a systematic review of the evidence found no proof that CLL increases the risk of autoimmune conditions affecting organs outside the blood system. Likewise, there is no clear epidemiological evidence that having a non-blood autoimmune disease increases a person’s risk of developing CLL.

That said, a few rare non-blood autoimmune conditions have been linked to CLL. A clear relationship exists with acquired angioedema (caused by a protein secreted by the tumor), glomerulonephritis (kidney inflammation), and paraneoplastic pemphigus (a blistering skin disease).³ The last two seem to result from the disordered immune environment rather than from a direct product of the tumor, and they can sometimes be triggered by treatment with certain chemotherapy drugs, hinting at a mechanism involving T-cell regulation.¹⁶ These are uncommon enough that clinicians encountering them may not immediately suspect CLL involvement, which can delay diagnosis.

When CLL Treatment Triggers Autoimmune Flares

One of the more alarming discoveries in CLL management has been that some effective cancer treatments can provoke or worsen autoimmune complications. Fludarabine, a chemotherapy drug that was once a cornerstone of CLL treatment, became notorious for this. In one series of 52 CLL patients treated with fludarabine, 12 developed severe autoimmune hemolytic anemia, and most of them had no prior history of the condition. Worse, when patients whose hemolysis had been controlled were retreated with fludarabine, three-quarters of them relapsed.¹⁷ Other case reports confirmed the pattern: the drug could tip the immune balance far enough to unmask or amplify autoimmune destruction of red blood cells.¹⁸

The mechanism likely involves fludarabine’s deep suppression of T cells. By stripping away the regulatory cells that keep bystander B cells in check, the drug can inadvertently unleash autoantibody production even as it kills CLL cells. This created a practical dilemma for years: the most effective drugs against the cancer were, in some patients, the worst possible trigger for the autoimmune problems that came with it.

Newer targeted therapies, including BTK inhibitors like ibrutinib, the PI3K inhibitor idelalisib, and the BCL-2 inhibitor venetoclax, have changed this landscape. These drugs have shown strong effectiveness against CLL and have also emerged as an alternative strategy for managing CLL-associated autoimmune complications.¹⁹ Ibrutinib in particular has been reported to resolve autoimmune cytopenias in patients where prior treatments had failed, though the newer agents are not entirely free of immune side effects either.

Animal Models That Blur the Line Further

Some of the most revealing evidence about the CLL-autoimmunity overlap comes from mice. The New Zealand Black (NZB) mouse strain is a naturally occurring model that develops a condition closely resembling human CLL. These mice first show B-cell overproduction and autoimmune features early in life, then progress to full-blown leukemia as they age.²⁰ The sequence matters: autoimmunity appears first, cancer second, suggesting the two are not just co-travelers but that one may feed the other.

A recent study using a different mouse model pushed this idea further. In mice engineered to express an active RANK receptor in B cells, autoimmune manifestations and CLL coexisted. When the researchers looked closely, they found near-identical antigen-recognition regions in both the plasma cells driving autoimmunity and the leukemic cells, suggesting both descended from a shared ancestor cell responding to the same antigen. Critically, when they genetically blocked the formation of autoimmune-driving plasma cells, CLL progression nearly halted, even though early B-cell proliferation was initially enhanced.²¹ The implication is provocative: autoimmune activity may not merely accompany CLL but actively promote its progression. If the same turns out to hold in humans, treating the autoimmune component early might slow the cancer, not just improve symptoms.

The Precursor Stage and Shared Roots

Before CLL becomes CLL, many patients pass through a precursor state called monoclonal B-cell lymphocytosis, in which a small clone of CLL-like B cells circulates in the blood without causing symptoms. Not everyone with this condition progresses to leukemia. Recent single-cell genomic work has identified a key transition point within this precursor stage where the biological features that distinguish indolent clones from those headed toward leukemia first emerge.²² The autonomous B-cell receptor signaling described earlier, where cells stimulate themselves without external antigen, has been observed even at this precursor stage, suggesting the self-reactive wiring is present long before the disease becomes clinically significant.⁸

This raises an interesting question for researchers: could monitoring for signs of autoimmune activation or autoreactive signaling in precursor clones help predict which patients are more likely to progress to CLL? No clinical tool like that exists yet, but the biology is pointing in that direction.

Shared Genetics Between Lymphoma and Autoimmune Disease

Beyond the cellular and immunological overlap, there are hints of shared genetic susceptibility. Genome-wide association studies have explored whether the same chromosomal regions that increase risk for autoimmune diseases also increase risk for lymphoid cancers. Several overlapping genomic regions have been identified, particularly in the HLA class II region, a stretch of DNA that plays a central role in how the immune system distinguishes self from non-self. In some cases, the same genetic variant increases risk for one condition while decreasing risk for another, a finding that underscores how intimately intertwined the pathways of immune surveillance and immune self-attack really are.²³

This kind of genetic overlap does not mean CLL is an autoimmune disease. It means the two conditions share some of the same biological soil. The immune system’s ability to distinguish threats from self-tissues is a tightrope walk, and the genetic factors that make someone more likely to stumble in one direction (autoimmunity) are sometimes the same ones that increase risk of stumbling in another (lymphoid malignancy). CLL occupies a distinctive niche where both kinds of stumble happen simultaneously, which is why the question of whether it “is” an autoimmune disease keeps coming up, even though the formal answer remains no.